Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Glioblastoma 3Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Glioma 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioblastoma × azeliragon × 1 year × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT06831526 2026-05-29

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Phase EARLY_PHASE1 Recruiting
12 enrolled
CNS

Glioblastoma

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡